{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:02:43Z","timestamp":1790665363724,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA154710-04"],"award-info":[{"award-number":["5R01CA154710-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001453","name":"American Brain Tumor Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.radonc.2017.08.009","type":"journal-article","created":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T22:19:04Z","timestamp":1505254744000},"page":"80-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control"],"prefix":"10.1016","volume":"125","author":[{"given":"Yi","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty Y.S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack M.","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M.","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Haydu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Kluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella C.","family":"Glitza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik P.","family":"Sulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica L.S.","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2017.08.009_b0005","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1158\/2326-6066.CIR-14-0069","article-title":"Combining radiation and immunotherapy: a new systemic therapy for solid tumors?","volume":"2","author":"Tang","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.radonc.2017.08.009_b0010","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.radonc.2017.08.009_b0015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.radonc.2017.08.009_b0020","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2567.2000.00121.x","article-title":"CD28, CTLA-4 and their ligands: who does what and to whom?","volume":"101","author":"Sansom","year":"2000","journal-title":"Immunology"},{"key":"10.1016\/j.radonc.2017.08.009_b0025","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2017.08.009_b0030","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2017.08.009_b0035","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2017.08.009_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2016.06.003","article-title":"Radiotherapy and immune checkpoints inhibitors for advanced melanoma","volume":"120","author":"Filippi","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2017.08.009_b0045","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/2326-6066.CIR-13-0115","article-title":"An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer","volume":"1","author":"Golden","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.radonc.2017.08.009_b0050","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1056\/NEJMc1203984","article-title":"Abscopal effect in a patient with melanoma","volume":"366","author":"Hiniker","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2017.08.009_b0055","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s12029-011-9294-9","article-title":"A man with Klinefelter\u2019s syndrome and new abdominal distension: a discussion of evaluation and management","volume":"43","author":"Postow","year":"2012","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.radonc.2017.08.009_b0060","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.radonc.2016.07.013","article-title":"Immune modulation by hypofractionated stereotactic radiation therapy: therapeutic implications","volume":"120","author":"Popp","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2017.08.009_b0065","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","article-title":"Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90\u201305","volume":"47","author":"Shaw","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.08.009_b0070","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","article-title":"X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization","volume":"10","author":"Camp","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.08.009_b0075","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/j.1349-7006.2008.00942.x","article-title":"Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA)","volume":"99","author":"Kountourakis","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.radonc.2017.08.009_b0080","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jnci\/86.11.829","article-title":"Dangers of using \u201coptimal\u201d cutpoints in the evaluation of prognostic factors","volume":"86","author":"Altman","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2017.08.009_b0085","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdt027","article-title":"Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival","volume":"24","author":"Delyon","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2017.08.009_b0090","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/cncr.24951","article-title":"Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival","volume":"116","author":"Ku","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2017.08.009_b0095","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.1200\/jco.2012.30.15_suppl.8575","article-title":"Evaluation of the absolute lymphocyte count as a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3mg\/kg)","volume":"30","author":"Postow","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2017.08.009_b0100","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.semradonc.2013.05.009","article-title":"Radiation as an immune modulator","volume":"23","author":"Burnette","year":"2013","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2017.08.009_b0105","doi-asserted-by":"crossref","first-page":"e28518","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.radonc.2017.08.009_b0110","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.onc.1210909","article-title":"Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer","volume":"27","author":"Roses","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.radonc.2017.08.009_b0115","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ijc.28015","article-title":"Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer","volume":"133","author":"Vermeer","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.radonc.2017.08.009_b0120","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1158\/2326-6066.CIR-13-0141","article-title":"Harnessing the potential of radiation-induced immune modulation for cancer therapy","volume":"1","author":"Ahmed","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.radonc.2017.08.009_b0125","first-page":"964","article-title":"Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft","volume":"56","author":"Znati","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.08.009_b0130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.radonc.2017.08.009_b0135","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.08.009_b0140","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-014-1617-9","article-title":"Ipilimumab and whole brain radiation therapy for melanoma brain metastases","volume":"121","author":"Gerber","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2017.08.009_b0145","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2017.08.009_b0150","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-015-0095-8","article-title":"Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review","volume":"3","author":"Schoenfeld","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.radonc.2017.08.009_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cam4.315","article-title":"Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery","volume":"4","author":"Tazi","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.radonc.2017.08.009_b0160","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2017.08.009_b0165","article-title":"Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases","author":"Patel","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2017.08.009_b0170","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","article-title":"Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment","volume":"92","author":"Kiess","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2017.08.009_b0175","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3171\/2012.5.JNS111929","article-title":"Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival","volume":"117","author":"Knisely","year":"2012","journal-title":"J Neurosurg"},{"key":"10.1016\/j.radonc.2017.08.009_b0180","first-page":"1","article-title":"The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab","author":"Cohen-Inbar","year":"2017","journal-title":"J Neurosurg"},{"key":"10.1016\/j.radonc.2017.08.009_b0185","doi-asserted-by":"crossref","first-page":"e1283461","DOI":"10.1080\/2162402X.2017.1283461","article-title":"Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab","volume":"6","author":"Skrepnik","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.radonc.2017.08.009_b0190","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1016\/S1470-2045(15)00141-2","article-title":"Evolving treatment options for melanoma brain metastases","volume":"16","author":"Ajithkumar","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2017.08.009_b0195","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs. stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2017.08.009_b0200","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2017.08.009_b0205","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/annonc\/mds263","article-title":"Evolution of end points for cancer immunotherapy trials","volume":"23","author":"Hoos","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2017.08.009_b0210","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.radonc.2017.08.009_b0215","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.radonc.2017.08.009_b0220","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","article-title":"CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients","volume":"19","author":"Ott","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2017.08.009_b0225","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/cr.2015.3","article-title":"Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25","volume":"25","author":"Hannani","year":"2015","journal-title":"Cell Res"},{"key":"10.1016\/j.radonc.2017.08.009_b0230","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.4049\/jimmunol.157.4.1333","article-title":"CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis","volume":"157","author":"Perrin","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.radonc.2017.08.009_b0235","doi-asserted-by":"crossref","first-page":"10150","DOI":"10.1158\/0008-5472.CAN-10-1852","article-title":"Active immunotherapy induces antibody responses that target tumor angiogenesis","volume":"70","author":"Schoenfeld","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2017.08.009_b0240","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3171\/2015.6.JNS142763","article-title":"Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?","volume":"125","author":"Colaco","year":"2016","journal-title":"J Neurosurg"},{"key":"10.1016\/j.radonc.2017.08.009_b0245","doi-asserted-by":"crossref","DOI":"10.1007\/s11060-017-2470-4","article-title":"Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma","author":"Fang","year":"2017","journal-title":"J Neurooncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814017325161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814017325161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T19:11:59Z","timestamp":1692990719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814017325161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0167814017325161"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2017.08.009","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2017.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}